Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03072485 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers

A Phase 1 study of Aging, sponsored by Anne Chang.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT03072485 is a Phase 1 study of Aging that has completed, run by Anne Chang. The registered enrollment target is 10 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03072485, a Phase 1 study of Aging, has completed, sponsored by Anne Chang.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This is a phase 1 study in healthy adult volunteers to examine the effects of 3 FDA approved medications on skin aging when applied in topical form. This is an open label, placebo controlled study.

Conditions Studied

Interventions

  • DRUG Sirolimus
  • DRUG Metformin
  • DRUG Diclofenac

Study Locations (1)

California

  • Stanford Dermatology - Redwood City

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2017-03-01
Est. Completion 2019-02-22
Phase Phase 1

Sponsor

Anne Chang

5 total trials

What the Registry Record Tells You About NCT03072485

The ClinicalTrials.gov registry entry for NCT03072485 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (100% lower). The listed sponsor is Anne Chang, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Aging appearing as the primary indexed condition, and to 3 interventions - of which Sirolimus is the first listed.

NCT03072485 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03072485 about?

NCT03072485 is a clinical study titled "Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers". This is a phase 1 study in healthy adult volunteers to examine the effects of 3 FDA approved medications on skin aging when applied in topical form. This is an open label, placebo controlled study.

What is the current status of trial NCT03072485?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-03-01. Estimated completion is 2019-02-22.

What conditions does trial NCT03072485 study?

This clinical trial studies the following conditions: Aging.

What interventions are being tested in trial NCT03072485?

The interventions under investigation include: Sirolimus (DRUG), Metformin (DRUG), Diclofenac (DRUG).

Who is sponsoring clinical trial NCT03072485?

This trial is sponsored by Anne Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03072485 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.